Simplify Logo

Full-Time

Director Toxicology

Rare Disease

Confirmed live in the last 24 hours

Acadia Pharmaceuticals Inc.

Acadia Pharmaceuticals Inc.

501-1,000 employees

Develops therapies for neurological disorders

Consulting
Biotechnology

Compensation Overview

$187k - $234.4kAnnually

+ Bonus + Equity Awards

Senior, Expert

San Diego, CA, USA

Category
Lab & Research
Medical Research
Required Skills
Communications
Marketing
Data Analysis
Requirements
  • PhD or DVM in a relevant discipline in a related field
  • Targeting 10 years of relevant experience in pre-clinical safety assessment/toxicology supporting drug development experience within the pharmaceutical or biotech industry. DABT Certification strongly preferred. An equivalent combination of relevant education and experience may be considered
  • Advanced understanding of the drug development process and the principles, concepts, practices, and standards of executing preclinical safety assessment/toxicology strategies
  • Broad knowledge in the tools and procedures of preclinical safety assessment/toxicology experimentation, including the various experimental designs, statistical tools of data analyses, software applications available for data manipulation and presentation, and instrumentation pertinent to the research. Through a complete understanding of the tools and design methods, able to evaluate the advantages and disadvantages of each, in terms of applicability to the research at hand
  • In depth knowledge of the preclinical study types necessary during drug development, including acute and chronic toxicology, safety pharmacology, developmental and reproductive toxicology, genotoxicity and carcinogenicity
  • Experience managing cross-functional project teams and working in a semi-virtual environment including CROs and academic collaborations
  • Specific direct study monitoring experience on Good Laboratory Practices (GLP) safety assessment/toxicology studies at CROs
  • Experience in the composition and review of preclinical safety assessment/toxicology reports with respect to accuracy, quality and compliance
  • Knowledge and understanding of GLP, ICH and FDA guidance, and other relevant regulations and guidelines
  • Demonstrated skills and abilities in coaching, influencing, facilitation, development, and problem solving
  • Excellent communication, presentation, consultative, partnership, and interpersonal skills
  • Ability to elicit cooperation from a wide variety of sources and to be persuasive, encouraging and motivating
  • Ability to learn, understand and apply new technologies, strategies and approaches that enhance the team’s ability to achieve goals and meet timelines/deliverables
  • Self-motivation and ability to work with limited supervision
Responsibilities
  • Plans experimental safety assessment/toxicology programs to include design, logistics, resource allocation, schedules. Identifies critical support needs, and other necessary details to implement the program(s)
  • Provides oversight on scientific management of preclinical safety assessment/toxicology studies supporting early drug development spanning lead optimization through IND and NDA submissions and nonclinical post marketing approval requirements
  • Monitors CROs for quality and compliance in the conduct of preclinical safety assessment/toxicology studies
  • Manages vendors and consultants to complete Translational Medicine safety assessment/toxicology studies for the various programs
  • Helps support preparation of reports and regulatory documents for IND and NDA submissions
  • Supports business development related nonclinical Tox/ADME assessments and due diligence projects by assessing available study data and regulatory submissions, defining additional nonclinical study plans and test compound requirements, and developing overall project timelines and associated budgets
  • Supports Impurity/Degradant safety assessment reviews requested by Chemistry, Manufacturing, and Controls (CMC) groups, involving public domain literature reviews, evaluating structure activity relationships using in silico databases, and competitive intelligence sources
  • Works across functional areas on projects including initiating/attending sub-team meetings and organizing ad hoc working groups as needed to move project activities forward
  • Communicates project status and issues and ensures project team goals and regulatory deliverables are met
  • Provides guidance to team members to objectively assess and resolve preclinical safety assessment/toxicology project issues to improve project effectiveness
  • Other duties as assigned
Acadia Pharmaceuticals Inc.

Acadia Pharmaceuticals Inc.

View

Acadia Pharmaceuticals develops therapies for neurological disorders, focusing on conditions like Parkinson's disease, schizophrenia, and Rett syndrome. Their products are created through extensive research and development, followed by rigorous clinical trials to ensure safety and effectiveness. Once approved by regulatory bodies like the FDA, these therapies are marketed to patients and healthcare providers. Acadia stands out from competitors by concentrating on areas with significant unmet medical needs and fostering strategic partnerships to enhance their research and market presence. The company's goal is to improve the quality of life for individuals with neurological conditions through effective treatments.

Company Stage

IPO

Total Funding

$813.4M

Headquarters

Dallas, Texas

Founded

1993

Simplify Jobs

Simplify's Take

What believers are saying

  • Acadia's launch of Magnolia's Guide to Adventuring showcases their innovative approach to raising disease awareness and redefining perceptions of Rett syndrome.
  • The acceptance of trofinetide for priority review by Health Canada could lead to significant market expansion and first-mover advantage in treating Rett syndrome in Canada.
  • The appointment of Dr. Elizabeth H. Z. Thompson as Executive Vice President, Head of Research and Development, signals a strong commitment to advancing their R&D capabilities.

What critics are saying

  • The failure of the Phase III ADVANCE-2 trial for pimavanserin in schizophrenia highlights the high-risk nature of drug development in the biopharmaceutical sector.
  • Dependence on regulatory approvals, such as the FDA and Health Canada, introduces uncertainty and potential delays in bringing therapies to market.

What makes Acadia Pharmaceuticals Inc. unique

  • Acadia Pharmaceuticals focuses exclusively on neurological disorders, setting it apart from competitors with broader therapeutic areas.
  • Their commitment to corporate social responsibility, including initiatives like the Rett Sibling Scholarship, enhances their reputation and community engagement.
  • Acadia's strategic partnerships and corporate sponsorships amplify their research capabilities and market reach, distinguishing them from competitors who may not leverage such collaborations.